Last reviewed · How we verify
Dex2
At a glance
| Generic name | Dex2 |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) (PHASE2)
- The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP (PHASE2, PHASE3)
- Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis (PHASE2)
- Comparison Between Intranasal vs Intravenous Dexmedetomidine for EEG Sedation of Children With Behavior Disorders.
- Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children (PHASE1)
- Dexamethasone and Functional Outcome After TKA (PHASE4)
- Effect of Dexamethasone as Analgesic Treatment After Total Knee Arthroplasty (PHASE4)
- Effect of Dexamethasone Shortly Before Surgery on the Intraoperative Dose of Remifentanil (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dex2 CI brief — competitive landscape report
- Dex2 updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI